Trading involves risk
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Trading involves risk
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
English (International)
CureVac NV
Closed
5.42 -0.73
Overview
Share price change
24h
Min
5.39
Max
5.46
Income | -422M -52M |
|---|---|
Sales | -493M 893K |
P/E Sector Avg | 5.755 39.564 |
Profit margin | -5,784.434 |
Employees | 825 |
EBITDA | -422M -47M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | -23.63% downside |
Next Earnings | 14 Aug 2025 |
|---|
Market Cap | 491M 1.2B |
|---|---|
Previous open | 6.15 |
Previous close | 5.42 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
CureVac NV Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
CureVac NV Forecast
Price Target
By TipRanks
-23.63% downside
12 Months Forecast
Average 4.17 USD -23.63%
High 5.5 USD
Low 2 USD
Based on 5 Wall Street analysts offering 12 month price targets forCureVac NV - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About CureVac NV
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
